Back to Journals » Cancer Management and Research » Volume 12

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience

Authors Guo Q, Chen M, Xu H, Lu T, Zhou H, Chen Y, Zong J, Xu Y, Chen B, Wang B, Zhu L, Pan J, Lin S

Received 12 October 2019

Accepted for publication 25 January 2020

Published 25 February 2020 Volume 2020:12 Pages 1387—1396

DOI https://doi.org/10.2147/CMAR.S234271

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Eileen O'Reilly


Qiaojuan Guo, 1– 3,* Mengwei Chen, 4,* Hanchuan Xu, 1 Tianzhu Lu, 1 Han Zhou, 1 Yanyan Chen, 1 Jingfeng Zong, 1 Yun Xu, 1 Bijuan Chen, 1 Bingyi Wang, 1 Lili Zhu, 1 Jianji Pan, 1, 2 Shaojun Lin 1, 2

1Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People’s Republic of China; 2Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, People’s Republic of China; 3Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 4Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China

*These authors contributed equally to this work

Correspondence: Shaojun Lin
Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, No. 420 Fuma Road, Fuzhou 350014, People’s Republic of China
Tel +86 591-83638732
Fax +86 591-83928767
Email linshaojun@yeah.net

Background: In this study, we retrospectively evaluated a series of metastatic nasopharyngeal carcinoma (mNPC) patients who received oral maintenance chemotherapy using S-1/capecitabine after systemic chemotherapy and local radiation therapy, and aimed to explore potential efficient treatment strategies for this subset of patients.
Patients and Methods: Thirty-seven patients with mNPC (19 newly diagnosed metastatic patients and 18 metastatic cases after definitive chemoradiotherapy) who received the treatment strategies mentioned above were analyzed.
Results: After a median follow-up time of 37 months, the 3-year progression-free survival and overall survival (OS) rates were 47.6% and 87.7%, respectively. The median time to progression was 27.6 months, while the median OS was not reached at time of last follow-up. The most common acute adverse events were hematological and gastrointestinal toxicity, and all were tolerable and curable.
Conclusion: Oral maintenance chemotherapy using S-1/capecitabine in mNPC patients after systemic chemotherapy could yield a superb outcome. Further multicenter prospective clinical trials are warranted.

Keywords: metastatic nasopharyngeal carcinoma, maintenance chemotherapy, systemic chemotherapy, S-1, capecitabine

Corrigendum for this paper has been published

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]